Skip to main content

Table 5 Clinical data of included studies for the efficacy of SVR on the development of HCC in patients with CHC

From: Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Study Nationality Age Duration of follow up Study format Genotype NOS Treatment HCC/Total SVR HCC/No SVR Histology
Nishiguchi S et al. (1995) [51] Japan Tx: 54.7, control: 57.3 (mean) 2–7 years RCT 75.6% type 2   IFN-α 0/7 2/38 HAI 11.7 in Tx, 11.8 in control (mean)
Tanaka K et al. (1998) [52] Japan SVR: 47.7, no SVR: 51 (mean) about 40 months P unknown 7 lymphoblastoid IFN 0/8 10/47 LC
Yoshida H et al. (1999) [30] Japan Tx: 49.5, control: 53.6 (mean) median 4.3 years R 70.3% type 1 7 IFN-α or IFN-β or combination 10/789 79/1611 F3,4: 33.1% in Tx, 33.8% in control
Testino G et al. (2002) [16] Italy Tx: 55.3, control: 56.8 (mean) mean 95.4 months R 55% type 1b, 45% type 2 8 IFN-α 3/11 12/40 Child A LC
Okanoue T et al. (2002) [53] Japan Tx: 50.4, control: 58.1 (mean) Mean 5.6 years R unknown 7 IFN-α or lymphoblastoid 4/426 110/994 F3,4: 20.9% in SVR, 34.4% in control
Coverdale SA et al. (2004) [36] Australia Tx: 37, control: 38 (median) median 9 years P 39.6% type 1 7 IFN-α 1/50 25/334 Scheuer fibrosis score 2
Shiratori Y et al. (2005) [38] Japan Tx: 57, control: 61 (median) median 6.8 years P 71.9% type 1b 8 IFN-α or lymphoblastoid 11/64 73/207 unknown
Yu ML et al. (2006) [39] Taiwan Tx: 46.9, control: 43.6 (mean) mean 5.18–5.15 years R 46.2% type 1 8 IFN-α with or without RBV 12/715 39/342 LC 15.6% in Tx, 12.1% in control
Pradat P et al. (2007) [54] Europe 45–47 (mean) 5–7 years P 49.2% type 1 6 IFN/PegIFN with or without RBV 0/91 17/266 unknown
Braks RE et al. (2007) [55] France 54.1 (mean) mean 7.7 years R 61.1% type 1 8 IFN-α with or without RBV, or PegIFN with RBV 1/37 24/76 Child A LC
Bruno S et al. (2007) [56] Italy 54.7 (mean) Mean 96.1 months R 71.8% type 1 8 IFN-α 7/124 122/759 Child A LC
Hasegawa E et al. (2007) [57] Japan 56 (median) median 4.6 years R 65% 2a 7 IFN-α,β/lymphoblastoid with or without RBV 3/48 16/57 LC
Veldt BJ et al. (2007) [58] Europe and Canada 48 (median) median 2.1 years R 59% type 1 8 IFN/PegIFN with or without RBV 3/142 32/337 Ishak 4–6
Floreani A et al. (2008) [59] Italy 44.5–55.7 (mean) mean 23.4–25.2 months R 41.3% type 1 7 PegIFN with RBV 0/40 5/38 unknown
Sinn DH et al. (2008) [40] Korea 48.4–58.2 (mean) median 55.2 months R 48.6% type 2 7 IFN/PegIFN with or without RBV 4/296 10/194 F3,4: 49% in Tx, F4: 33% in control
Kurokawa M et al. (2009) [60] Japan 55.8 (mean) median 36.5 months R 72.9% type 1 7 IFN-α with RBV 4/139 21/264 F3,4: 31.3%
Asahina Y et al. (2010) [61] Japan 55.4 (mean) mean 7.5 years R 69.6% type 1b 8 IFN-α,β with or without RBV, or PegIFN with RBV 22/686 149/1356 F3,4: 25.2%
Kawamura Y et al. (2010) [62] Japan 50 (median) median 6.7 years R unknown 8 IFN-α,β with or without RBV 12/1081 61/977 F1,2: 93.1%
Cardoso AC et al. (2010) [63] France 55 (mean) median 3.5 years R 60% type 1 7 IFN/PegIFN with or without RBV 6/103 40/204 F3,4: 100%
Morgan TR et al. (2010) [64] US 48.6–49.6 (mean) median 79–96 months P 87.2% type 1 8 PegIFN with or without RBV 2/140 33/386 F3,4: 100%
Di Martino V et al. (2011) [41] France unknown median 59 months R 57.9% type 1 7 IFN with or without RBV, or PegIFN with RBV 1/59 8/125 55.5% F2 or greater
Velosa J et al. (2011) [65] Portugal 51.7 (mean) mean 6.4 years R 61% type 1 7 IFN/PegIFN with or without RBV 1/39 20/91 compensated LC
Iacobellis A et al. (2011) [66] Italy 59–62 (mean) mean 51 months P 57.3% type 1 7 PegIFN with RBV 5/24 11/51 decompensated LC
Hung CH et al. (2011) [67] Taiwan 53 (median) median 4.3 years R 49% type 1 7 IFN/PegIFN with or without RBV 33/1027 54/443 unknown
Takahashi H et al. (2011) [68] Japan 55.4 (mean) Mean 52 months R 74.9% type 1b 7 IFN-α,β/PegIFN with RBV 1/89 12/114 F3,4: 23.2%
Backus LI et al. (2011) [69] US 51–53 (mean) median 3.8 years R 72.1% type 1 6 PegIFN with RBV 223/7434 283/1440 13% LC
Tateyama M et al. (2011) [42] Japan 57 (median) mean 8.2 years R 72.1% type 1b 8 IFN/PegIFN with or without RBV 3/139 44/234 F3,4: 34.1%
Osaki Y et al. (2012) [70] Japan 59 (median) median 4.1 years R 59.9% type 1 7 IFN/PegIFN with RBV 1/185 22/197 unknown
van der Meer AJ et al. (2012) [71] Europe and Canada 48 (mean) median 8.4 years R 68% type 1 8 IFN/PegIFN with or without RBV 7/125 76/405 Ishak 4–6
Maruoka D et al. (2012) [43] Japan 50.4–54 (mean) mean 9.9 years R 73.6% type 1 8 IFN-α/IFN-β with or without RBV 5/221 80/356 F3,4: 24.3% in Tx, F4: 43.1% in control
Cozen ML et al. (2013) [44] US 50.98 (mean) mean 10 years R 68.7% type 1 8 IFN-α with or without RBV 2/69 9/90 F3,4: 19% (30.2% in Tx, 10.1% in control)
Alfaleh FZ et al. (2013) [72] Saudi Arabia, Egypt 48 (mean) mean 63.8 months P 30.6% type 4 8 PegIFN with or without RBV 0/62 4/95 F3,4: 24.6% (27.1% in SVR, 31.1% in no SVR)
Aleman S et al. (2013) [45] Sweden 51 (mean) mean 5.3 years R 50% type 1 8 PegIFN with RBV 6/110 26/193 LC
Di Marco V et al. (2016) [73] Italy 58 (mean) median 7.6 years P 83.4% type 1 8 PegIFN with RBV 7/108 92/336 compensated LC
Ikezaki H et al. (2016) [74] Japan 60–64 (median) median 2.8 years R 52.7% in type 1 7 IFN- β with RBV 2/68 7/44 F3,4: 30.9% in SVR, 72.7% in no SVR
  1. SVR sustained virologic response, HCC hepatocellular carcinoma, CHC chronic hepatitis C, NOS Newcastle-Ottawa scale, Tx treatment group, R retrospective cohort study, P prospective cohort study, RCT randomized controlled study, IFN interferon, PegIFN pegylated interferon, RBV ribavirin, LC liver cirrhosis